《大行報告》中金升思摩爾(06969.HK)目標價至17.6元 評級「跑贏行業」
中金發表評級報告指,思摩爾(06969.HK)近日披露首個自研自造的「呼吸機聯合用網式霧化器系統」在台灣獲金點年度最佳設計獎,為全球電子霧化行業獲得的首個醫療裝置獎項,標誌思摩爾的醫療霧化新板塊取得實質性突破,也意味著公司的持續高強度研發投入正逐步進入收獲期,助力公司中長期可持續成長。
報告補充,公司醫療網式霧化系統在技術、設計、專利資質等多維度均表現亮眼,今年起有望帶來收入貢獻,後續公司「藥械一體」佈局有望落地;另外,海外大客戶份額有望持續提升,內地市場需求短期預計承壓,中長期滲透空間廣闊,故該行預計明年公司大客戶的美國PMTA審核有望完成,公司料憑借其符合監管要求的客戶產品實現份額持續提升。
中金表示,維持公司在2022年至23年盈利預測不變,預料2024年盈利為33.5億元人民幣,並將其目標價上調28%至17.6元,維持「跑贏行業」評級。(ca/s)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.